Algorae Pharmaceuticals Limited
LVCLF
$0.0063
$0.000916.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 42.55% | 22.85% | 3.22% | 10.07% | 15.21% |
| Total Depreciation and Amortization | -- | -- | -- | -60.00% | -33.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.16% | 235.22% | 3,665.69% | 5,695.31% | 855.68% |
| Change in Net Operating Assets | -310.42% | -310.42% | -310.42% | -296.84% | 322.52% |
| Cash from Operations | 34.40% | 29.11% | 25.35% | 29.70% | 32.56% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 191.30% | 5,332.50% | -127.08% | -162.54% | -197.36% |
| Cash from Investing | 191.30% | 5,332.50% | -127.08% | -162.67% | -197.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.07% | -87.06% | -73.38% | -43.36% | -25.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 83.55% | 83.55% | 83.55% | -18.52% | -5,850.00% |
| Cash from Financing | -99.90% | -87.94% | -72.66% | -12.29% | 71.32% |
| Foreign Exchange rate Adjustments | -128.07% | -126.32% | -124.56% | 184.00% | 152.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.22% | -449.57% | -245.17% | -416.69% | -19.55% |